Business Context and Reporting Period
Company: Inhibikase Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 19, 2025
Reporting Period: Event-specific (December 19, 2025)
Context: The Company is an emerging growth company incorporated in Delaware. This filing reports the activation of an "at the market" (ATM) equity offering program.
Key Financial Metrics
This filing does not contain periodic financial statements (e.g., revenue, profit, cash flow, or margins). The primary financial metric disclosed is the potential capital raise:
- Proposed Offering Amount: Up to $185,000,000 in aggregate offering price.
- Security Type: Common Stock, $0.001 par value (Trading Symbol: IKT).
- Sales Agent: Jefferies LLC.
Material Changes
The material change reported is the filing of a Prospectus Supplement dated December 19, 2025, which expands the Company's ability to sell shares under its existing ATM Program. This action is based on a Registration Statement on Form S-3 (File No. 333-288213) previously declared effective on June 27, 2025.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates the Company intends to sell shares "from time to time" through Jefferies LLC pursuant to the Open Market Sale Agreement dated June 20, 2025.
Risks and Contingencies: The filing text does not explicitly detail specific risks or contingencies associated with this offering, other than the standard nature of an equity offering which may dilute existing shareholders. The filing incorporates by reference the Sales Agreement and legal opinions for further details.
Investor Verification Checklist
- Verify the current market price of IKT to assess potential dilution from the $185 million offering.
- Review the Open Market Sale Agreement (Exhibit 1.1) for commission rates and termination clauses.
- Check the Company's most recent 10-K or 10-Q for current cash runway and liquidity needs driving this capital raise.
- Confirm the status of the underlying Form S-3 registration statement (File No. 333-288213).